Introduction
============

The GABA~A~ receptor (GABA~A~R) is the most important inhibitory receptor channel complex in the central nervous system (CNS). It is a pentameric ligand-gated ion channel, which is activated by γ-aminobutyric acid (GABA) and is modulated by various compounds. GABA~A~R modulators include benzodiazepines, barbiturates, propofol, ethanol, neurosteroids, cations (e.g., zinc ions), herbal components and odorants as well as the neurotransmitter histamine ([@B6]; [@B22]; [@B40]; [@B11]; [@B14]; [@B16]; [@B3]; [@B21]; [@B30]; [@B34]; [@B29]; [@B17]; [@B44]). Since 2008, it has been known that histamine could directly activate homomeric GABA~A~Rs composed of β subunits and modulate the heteromeric GABA~A~Rs α1β2 and α1β2γ2 ([@B30]). The modulatory effects of histamine on heteromeric GABA~A~Rs depend on the subunit composition of the receptors ([@B4]). Today, 19 subunits are known ([@B37]). These subunits are α1--6, β1--3, γ1--3, δ, ε, 𝜃, π, and ρ1--3. [@B4] showed α subunit preference of histamine under low GABA concentrations.

Histamine is a neurotransmitter in the brain and a cytokine in the periphery. It is produced and released by mast cells, basophiles, enterochromaffin-like cells, and neurons ([@B12]). In the brain histamine is released from the tuberomammillary nucleus which is involved in the wake-sleep regulation. Metabotropic histamine receptors (H~1~--H~4~) mediate the physiological functions of histamine but at least three different types of neuronal ligand-gated ion channels are modulated by histamine ([@B2]; [@B30]; [@B4]; [@B17]). The possible mechanism of the modulation of GABA~A~Rs in the brain is still speculative ([@B30]; [@B4]).

Currently, the interaction site for histamine on the GABA~A~R is unknown. There are many known modulation sites on the GABA~A~Rs for various compounds. These sites include the amino acids β2(N265) and β2(M286). These two amino acid residues are involved in the propofol and etomidate interaction with the GABA~A~Rs ([@B18]; [@B35]; [@B15]; [@B28]). These amino acid residues represent some of the different modulation mechanisms of the receptor. Propofol and etomidate are positive modulators of the GABA~A~Rs. In addition to these described modulation sites, there are other identified sites of functional relevance. These sites are, e.g., the GABA-binding site, which involves the amino acid residue F64 of the α subunit and the amino acid residues Y157 and Y205 of the β subunits ([@B36]; [@B1]). Recent studies with mutated amino acids V175, Q185, and D163 of the β subunit and R120 of the α subunit, which are components of loop nine or are involved in a salt-bridge interaction, show that these amino acids are involved in stabilizing the closed state or involved in a state-dependent salt-bridge of the GABA~A~Rs ([@B42]; [@B20]).

While binding sites on the GABA~A~Rs have already been described for some allosteric modulators, the molecular basis of positive allosteric receptor modulation by histamine is unknown. Therefore, we plan to identify the amino acids that are involved in the modulatory effect of histamine at the GABA~A~Rs. For that purpose, we investigated site-directed mutated GABA~A~Rs expressed in a *Xenopus laevis* expression system using the two-electrode voltage clamp technique, and analyzed the structural impact of the chosen amino acids by creating a homology model of a 2x α1 -- 3x β3 GABA~A~Rs heteropentamer.

Materials and Methods {#s1}
=====================

GABA~A~R cDNA
-------------

Expression plasmids based on the pSGEM vector (courtesy of M. Hollmann, Bochum, Germany) for rat α1, β2, mouse γ2L, and human β3 were described by [@B30]. Rat α2 cDNA was kindly provided by ImaGenes, Berlin, Germany, and subcloned into pSGEM by using PCR and standard molecular biology methods.

The point mutations were made using overlap-extension PCRs, as described by [@B13]. For overlap-extension PCRs, the plasmids for α1, β2, and β3 subunits were used as templates. Overlap-extension PCR was performed using a mixture of *taq*-DNA- and *pwo*-DNA-polymerase (20:1) (Biotherm) in a volume of 50 μl with 20 pmol of each primer (Supplementary Table [S3](#SM1){ref-type="supplementary-material"}). The following temperature cycle profile was used: 5 min at 95°C; followed by 30 cycles of 45 s at 95°C, 45 s at 60°C, 60 s at 72°C (120 s for the fusion PCR); and a final extension of 10 min at 72°C. The mutated DNA was subcloned into pSGEM using standard molecular biology methods.

Expression of Receptor cRNA in *Xenopus laevis* oocytes
-------------------------------------------------------

The cRNAs of wt as well as point mutated GABA~A~R subunit cRNAs were synthesized by using the AmpliCap T7 high yield message maker kit (Epicentre, Madison, WI, USA) as described by [@B34]. The oocytes were prepared from *Xenopus laevis* using standard methods. Five to twenty nanograms of cRNA was injected, 24 h after surgery, into one stage V--VI oocyte. The incubation took place at 12--16°C in ND96 \[96 mM NaCl, 2 mM KCl, 1.8 mM CaCl~2~, 1 mM MgCl~2~, 5 mM HEPES, pH 7.2; 100 U/ml penicillin, 100 U/ml streptomycin from Antibiotic Antimycotic Solution (100x)\] (Sigma--Aldrich, St. Louis, MO, USA). After 2--4 days, the oocytes were measured by two-electrode voltage clamp, as briefly described by [@B34]. Each of the tested substances was diluted with Frog-Ringer's solution (115 mM NaCl, 2.5 mM KCl, 1.8 mM CaCl~2~, 10 mM HEPES, pH 7.2). The agonists were dissolved in ND96 and applied in a volume of 200 μl into the entrance tube of the recording chamber, totally exchanging the bath solution within a second. Therefore, due to the relative slow desensitization kinetics in our investigated GABA receptors and the fact that we compare the same receptor ± histamine, desensitization will not interfere with the determination of the histamine potentiation. The pH of GABA- or histamine-containing solutions was monitored to ensure a pH of 7.2 for all histamine concentrations. All measurements were taken with a membrane potential of -40 mV.

Analysis and Statistics
-----------------------

During the measurements, the currents were recorded using CellWorks software and were analyzed using pCLAMP 10 software. The statistical evaluation and curve fitting (3-parameter Hill equation) was performed using SigmaPlot V8.0 (Systat Software, San Jose, CA, USA). All mean values are ± SEM, and the significant data were marked with ^∗^*p* ≤ 0.05, ^∗∗^*p* ≤ 0.01, and ^∗∗∗^*p* ≤ 0.001.

GABA~A~R Homology Modeling and Histamine Docking
------------------------------------------------

The 2.97 Å crystal structure of the GABA β3 homopentamer ([@B23]) was used as basis for homology modeling. We carried out a sequence alignment of the α1 sequence (Uniprot entry P14867, [@B39]) and the β3 subunit sequences from the crystal structure with MUSCLE ([@B9]; default settings). The resulting alignment showed 35.3% sequence identity and 61.9% sequence similarity and is included in the Supplementary Material. As we know from GPCR modeling, an identity \>35% is a good basis for homology modeling of transmembrane proteins ([@B43]; [@B19]). Based on this alignment, we created and optimized a model of an α1 subunit homopentamer with the SWISS-MODEL server ([@B5]), based on the structure of the β3 homopentamer from the crystal structure mentioned above. We then created a 2x α1 -- 3x β3 GABA~A~R heteropentamer by substituting two β3 subunits in the crystal structure (chain A and C) by the respective α1 subunits in PyMol ([@B32]). We then carried out a WHATIF protein check, showing that the model is reliable. The checkfile can be found in the Supplementary Material. Binding site analysis was carried out with TRIDOCK ([@B38]). In short, TRIDOCK searches for putative binding positions for small organic molecules following Congreve's rule-of-three ([@B8]) and marks these positions with a "bead." Docking calculations on histamine binding were carried out with Autodock Vina ([@B41]), using a 20 × 20 × 20 Å box (grid spacing 1 Å) centered between Asp163(β) and R120(α), and an exhaustiveness parameter of 80 ([@B31]). A histamine topology was obtained from the PRODRG server ([@B33]). Polar atoms and Kollman charges were added to the heteropentameric protein, while histamine was docked with Gasteiger charges.

Results
=======

Screening of Mutated GABA~A~Rs for Altered Histamine Potentiation
-----------------------------------------------------------------

[@B30] showed that homomeric β2 or β3 receptors were activated by histamine in a recombinant expression system. Our intention was to analyze the effect of histamine on point mutated GABA~A~R β2/3 subunits. First, we generated mutations in β2/3 subunits. In contrast to the wild-type (wt) subunits, functional expression of mutated GABA~A~Rs as homomeric receptors failed in most instances so that a systematic screening of homomeric receptors was not possible. Therefore, we had to determine the impact of mutated amino acids in heteromeric receptors by analyzing the potentiating effect of histamine on the GABA-induced currents. We were mostly interested in the effect of histamine on the two most important synaptic GABA~A~Rs of the CNS composed of α1β2γ2L and α2β3γ2L subunits ([@B27]; [@B25]; [@B26]).

To screen the modulating effect of histamine, we investigated the action of 3 mM histamine on currents evoked by GABA (typically EC~10-30~). To determine suitable GABA concentrations for screening experiments, the EC~50~ values of GABA for all of the investigated subunit combinations were determined (Supplementary Table [S1](#SM1){ref-type="supplementary-material"}). In addition, we tested histamine concentrations up to 10 mM to demonstrate the absence of homomeric GABA~A~Rs composed of β subunits. For all of our analyzed GABA~A~Rs, histamine alone did not induce any currents (data not shown).

First, we analyzed the wt GABA~A~Rs α1β2γ2L, α1β3γ2L, and α2β3γ2L, to demonstrate a robust and reproducible potentiation of GABA-induced currents by histamine under our experimental conditions. This analysis also served as control for our experiments with the point mutated GABA~A~Rs. With our experiments, we could show, as [@B30] had previously, that histamine could increase the GABA-induced current of wt receptors in a dose-dependent manner. Three millimolar histamine significantly potentiated the GABA-induced currents of GABA~A~Rs α1β2γ2L by approximately 1.4-fold, α1β3γ2L by approximately 0.6-fold and α2β3γ2L by approximately 0.7-fold (**Figure [1](#F1){ref-type="fig"}**).

![**GABA potentiated by histamine in wt receptors**. GABA-induced (EC~10-30~) currents are potentiated by 3 mM histamine. (A--C) *Xenopus* oocytes expressing the abg isoforms: α1β2γ2L, α1β3γ2L, and α2β3γ2L were voltage clamped, and GABA at a concentration of 10 μM was bath-applied with or without 3 mM histamine. **(D)** Average potentiation of GABA-induced currents calculated from measurements as shown in **(A--C)**. Bars two to four show the mean enhancement ± SEM, as a percentage of the amplitude of GABA alone (gray line), for the αβγ isoforms: α1β2γ2L, α1β3γ2L, and α2β3γ2L, (*n* = 9--12). Significant data were marked with ^∗^*p* ≤ 0.05, ^∗∗^*p* ≤ 0.01, and ^∗∗∗^*p* ≤ 0.001.](fphar-06-00106-g001){#F1}

Next, we screened all point mutated GABA~A~Rs using the same conditions: a GABA concentration of typical EC~10-30~ and a histamine concentration of 3 mM. The first amino acids to be analyzed for their action in the histamine modulation of the GABA~A~R were the point mutants β(N265M) and β(M286W). These amino acids are involved in the action of etomidate and propofol on the GABA~A~Rs ([@B18]; [@B35]; [@B15]; [@B28]). Our experiments showed that the GABA-induced currents (10 μM GABA) on GABA~A~Rs that contained the point mutated subunits β(N265M) or β(M286W) were increased by histamine (**Figure [2](#F2){ref-type="fig"}**). However, the histamine modulation of the mutated receptors was not significantly different from the modulation of the wt GABA~A~Rs α1β2γ2L. Therefore, these mutations do not influence histamine modulation.

![**Effect of 3 mM histamine on the GABA-induced current of wt or mutated GABA~A~Rs**. The bars show the increase of the GABA-induced (typically EC~10-30~) currents by 3 mM histamine of the GABA~A~R subunit combination **(A)** α1β2γ2L and **(B)** α2β3γ2L. Significant data were marked with ^∗^*p* ≤ 0.05 and ^∗∗^*p* ≤ 0.01.](fphar-06-00106-g002){#F2}

The next 10 amino acids that we analyzed are important for binding GABA, for forming a state-dependent salt-bridge or for stabilizing the closed state of the GABA~A~Rs ([@B1]; [@B42]; [@B20]). Furthermore, we were interested in the influence of the conserved leucine in the pore-forming TM2 segment that is involved in the gating-mechanism of the GABA~A~Rs ([@B7]). Because this amino acid, β2(L259), is also present in α subunits, we investigated point mutations of both a and β subunits. Receptors with the mutations β2(Y157F), β2(D163A), β3(V175A), and the combination of α1(R120A) with β2(D163A) showed significantly reduced potentiation of the GABA-induced current by histamine (**Figure [2](#F2){ref-type="fig"}**).

It can be suggested that the amino acids Y157, D163, and V175 of the β subunit and the amino acid R120 of the α subunit are involved in the action of histamine. The analyzed GABA~A~R α2β3(Q185A)γ2L showed a stronger potentiation than the wt demonstrating that the amino acid Q185 also potentially affects histamine action on GABA~A~Rs.

Dose-Dependent Action of Histamine on Mutated GABA~A~Rs
-------------------------------------------------------

To investigate the impact of the identified amino acids on histamine modulation in more detail, we next analyzed the effect of different histamine concentrations (0.1 to 10 mM) on the GABA-induced current (typically EC~10-30~).

The first amino acid residue we analyzed was Y157 of the β subunit. This amino acid residue is involved in the conformational changes in the GABA~A~Rs induced by GABA ([@B1]). GABA~A~R α1β2(Y157F)γ2L showed reduced potentiation of the GABA-induced current by 3 mM histamine (**Figure [2A](#F2){ref-type="fig"}**) in comparison to the wt α1β2γ2L receptor. Histamine concentrations of 0.1 to 10 mM potentiated the GABA-induced current in a dose-dependent manner (**Figures [3A,B](#F3){ref-type="fig"}**). However, for all of the tested concentrations, the potentiating effect was smaller than the effect observed with the wt receptor (**Figures [3B,C](#F3){ref-type="fig"}**, and Supplementary Table [S2](#SM1){ref-type="supplementary-material"}). To analyze the influence of the γ2L subunit, we co-expressed the subunits α1 and β2(Y157F). Histamine caused a dose-dependent potentiation of the mutated GABA~A~R (**Figures [3D,E](#F3){ref-type="fig"}**) that was not significantly different from the wt α1β2 receptor (**Figures [3E,F](#F3){ref-type="fig"}**, and Supplementary Table [S2](#SM1){ref-type="supplementary-material"}). Interestingly, the influence of the point mutations is dependent on the presence of the γ2L subunit. These results show that Y157 is not essential for potentiation by histamine.

![**Histamine action on GABA-induced currents of GABA~A~Rs with the point mutated β2(Y157F) subunit. (A,D)** Original traces of the histamine (3 mM) action on the GABA-induced currents of the GABA~A~Rs α1β2(Y157F)γ2L and α1β2(Y157F). **(B,C,E,F)** Bar diagrams show the action of various histamine concentrations on the GABA-induced currents of the GABA~A~Rs α1β2(Y157F)γ2L, α1β2(Y157F), α1β2γ2L, and α1β2. Significant data were marked with ^∗^*p* ≤ 0.05, ^∗∗^*p* ≤ 0.01, and ^∗∗∗^*p* ≤ 0.001.](fphar-06-00106-g003){#F3}

Next, we analyzed the effect of histamine on the amino acids α1(R120) and β2(D163), which form a state-dependent salt-bridge of the GABA~A~Rs ([@B20]). We investigated the ability of different histamine concentrations (0.1 to 10 mM) to potentiate the GABA response (typically EC~10-30~) on the GABA~A~Rs α1(R120A)β2γ2L, α1β2(D163A)γ2L, and α1(R120A)β2(D163A)γ2L (**Figure [4](#F4){ref-type="fig"}**). Histamine shows a dose-dependent potentiation on the GABA~A~Rs α1(R120A)β2γ2L and α1β2(D163A)γ2L (**Figures [4A,B,D,E](#F4){ref-type="fig"}**). However, at a receptor composed of both mutated subunits in combination with the γ2L subunit, the increasing effect of histamine is nearly abolished (**Figures [4C,F](#F4){ref-type="fig"}**). In comparison to wt, the mutation α1(R120A) alone had no significant effect on histamine potentiation (Supplementary Table [S2](#SM1){ref-type="supplementary-material"}). At GABA~A~Rs α1β2(D163A)γ2L and GABA~A~R α1(R120A)β2(D163A)γ2L (**Figure [3C](#F3){ref-type="fig"}**), histamine potentiation was significantly less than at the wt for most concentrations tested (Supplementary Table [S2](#SM1){ref-type="supplementary-material"}). To ensure that this effect is specific to histamine and does not abolish potentiation in general, we tested the potentiation of the GABA-induced currents by 10 μM propofol ([@B44]), which was able to potentiate the GABA-induced current (data not shown). To verify the influence of the γ2L subunit, we attempted to express the subunit combinations α1(R120A)β2, α1β2(D163A), and α1(R120A)β2(D163A), but none of these combinations produced a functional receptor.

![**Histamine action on GABA-induced currents of GABA~A~Rs with point mutated subunits α1(R120A) and β2(D163A). (A--C)** Original traces of the modulatory effect of 3 mM histamine on GABA-induced currents from GABA~A~Rs α1(R120A)β2γ2L, α1β2(D163A)γ2L, and α1(R120A)β2(D163A)γ2L. **(D--F)** Bar diagrams show the effect of 0.1 to 10 mM histamine on the GABA-induced (typically EC~10-30~) current. Significant data were marked with ^∗^*p* ≤ 0.05, ^∗∗^*p* ≤ 0.01, and ^∗∗∗^*p* ≤ 0.001.](fphar-06-00106-g004){#F4}

The last two amino acids that we analyzed were V175 and Q185 on the β subunit. These amino acids are located in loop 9, which is in close proximity to the salt-bridge formed by α1(R120A) and β2(D163A). The experiments with the GABA~A~R α2β3(V175A)γ2L showed that the GABA-induced current was not potentiated by histamine concentrations up to 3 mM (0.1 to 3 mM; **Figure [5](#F5){ref-type="fig"}**). Only the highest concentration, 10 mM, significantly changed the GABA-induced (EC~16~) current, increasing it 1.4-fold (**Figure [5B](#F5){ref-type="fig"}**). In comparison to the wt (**Figure [6C](#F6){ref-type="fig"}**), the potentiation effected by histamine is drastically reduced. This suggests that V175 is involved in the action of histamine on the GABA~A~Rs. To demonstrate that this effect is not dependent on the presence of the α2 subunit, we tested the α1β3(V175A)γ2L combination and also found a significant reduction in potentiation (Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}). To ensure that the loss of potentiation is specific for histamine, we tested this mutated receptor with 10 μM propofol, which caused a 1.8-fold potentiation (data not show) demonstrating that GABA-induced currents at this receptor can be potentiated by other modulators.

![**Histamine action on the GABA-induced currents of GABA~A~Rs with point mutated β3(V175A). (A)** Original trace of the effect of 3 mM histamine on the GABA-induced currents of the GABA~A~R α2β3(V175A)γ2L. **(B)** Bar diagram show the effect of various histamine concentrations up to 10 mM on the GABA-induced currents of the GABA~A~R α2β3(V175A)γ2L. Significant data were marked with ^∗∗^*p* ≤ 0.01.](fphar-06-00106-g005){#F5}

![**Histamine action on the GABA-induced currents of GABA~A~Rs with the point mutated β3(Q185A) subunit. (A)** Original trace of the histamine (3 mM) action on the GABA-induced (EC~11~) currents of the GABA~A~R α2β3(Q185A)γ2L. **(B,C)** Bar diagrams that show the action of different histamine concentrations on the GABA-induced currents of the GABA~A~Rs α2β3(Q185A)γ2L and α2β3γ2L. Significant data were marked with ^∗^*p* ≤ 0.05 and ^∗∗^*p* ≤ 0.01.](fphar-06-00106-g006){#F6}

In the initial screening, the potentiating effect of histamine appeared to be increased at GABA~A~R α2β3(Q185A)γ2L. The investigation of various histamine concentrations (0.01 to 10 mM) revealed a dose-dependent potentiation of the GABA (EC~11~) response (**Figures [6A,B](#F6){ref-type="fig"}**). In comparison to the wt receptor (**Figure [6C](#F6){ref-type="fig"}**), where the first significant potentiation was observed at 1 μM histamine, concentrations as low as 10 μM histamine produced significant potentiation at the α2β3(Q185A)γ2L receptor. For most concentrations up to 1 mM, histamine is a significantly better potentiator at the mutated receptor (Supplementary Table [S2](#SM1){ref-type="supplementary-material"}). At higher concentrations, the effect is no longer significant, which is an indication that the potency but not the efficacy of histamine is enhanced by this mutation. To demonstrate that this effect is not dependent on the presence of the α2 subunit, we tested the α1β3(Q185A)γ2L subunit combination and also found a significant increase in potentiation (Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}).

Discussion
==========

Our study confirms the recent finding ([@B30]; [@B4]) that there is a robust modulatory effect of histamine on GABA~A~Rs with different subunit combinations. The screening of point mutated GABA~A~R subunits revealed that most mutations, which encompass several amino acids conserved in β subunits, did not influence histamine potentiation. Our results demonstrate that the point mutations N265M and M286W of amino acids in the β subunit that are important for the modulation by etomidate and propofol ([@B35]; [@B15]; [@B28]) had no effect on the modulation of the GABA-induced current by histamine. Our results indicate that histamine does not act through these known modulation mechanisms.

In our work, we identified amino acid residues important for the modulatory action of histamine on GABA~A~Rs. Four amino acid residues are located on the β subunit, consistent with the idea proposed by [@B30] that the β subunit is involved in the action of histamine at the GABA~A~Rs. Most recently, the crystal structure of the human ß3 homopentameric receptor was resolved ([@B23]). To assess the potential function of the mutated amino acids, we build a homology model of an α1/β3 heteropentamer (**Figure [7](#F7){ref-type="fig"}**).

![**Overview of positions and functions of mutated residues**. Structural model based on PDB ID 4COF ([@B23]). Backbone displayed as cartoon, van der Waals surface as surface, selected residues as sticks, or balls and sticks, respectively. Extracellular domains visible as sheets, transmembrane domains as helical domains. Putative binding positions of small organic molecules according to TRIDOCK analysis ([@B38]) as orange spheres and histamine in magenta. Y157 is actively taking part in formation of the interface between the two subdomains. D163(β) and R120(α) form a putative histamine binding site at the interface between subdomains α and β. Q185 at the interface between transmembrane and extracellular domains is part of a hydrogen bonding network with the highly conserved residues E52 and R216. The V175 side chain is buried within the extracellular subdomains, and thus important for their correct folding. None of the investigated residues except D163(β) and R120(α) show a putative small molecule binding site.](fphar-06-00106-g007){#F7}

The point mutation β2(Y157F) was only effective in receptors containing the γ2L subunit and did not alter histamine's action on receptors composed solely of a and β subunits. This indicates that histamine does not directly interact with the amino acid Y157. The presence of the γ2 subunit alters the potentiation by histamine ([@B30]) and propofol ([@B35]). An indirect participation could be caused by an influence of amino acid Y157 on the interaction of γ2 with other subunits in a heteromeric receptor. This is supported by the location of Y157 in the homology model, as it is actively taking part in formation of the interface between the two extracellular subdomains (**Figure [7](#F7){ref-type="fig"}**).

A further amino acid residue that is involved in the modulatory effect of histamine is β3(Q185). This amino acid has a potentially negative impact on histamine potentiation, and the Q185A mutation enhances the effect of lower concentrations of histamine on the GABA~A~R. Q185 at the interface between transmembrane and extracellular domains is part of a hydrogen bonding network with the highly conserved residues E52 and R216 (**Figure [7](#F7){ref-type="fig"}**). The amino acid V175 resides inside the extra cellular domain and is of potential structural importance (**Figure [7](#F7){ref-type="fig"}**). Therefore, the Q185A or V175A mutations influence the histamine potentiation possibly by allosteric effects and are not part of a binding site.

The two amino acid residues that we identified as possibly being directly involved in the action of histamine on the GABA~A~R are R120 on the α subunit and D163 on the β subunit. Amino acid R120 is conserved in all α subunits; therefore, our data could be valid for all α subunits. [@B20] showed that these amino acids could be part of a state-dependent salt-bridge. This potential salt-bridge between R120 on the α subunit and D163 on the β subunit stabilizes the binding of GABA ([@B20]). Disruption of the salt-bridge on the α subunit by the R120A mutation greatly increases the EC~50~ of GABA. The D163A mutation on the β subunit clearly reduces histamine potentiation, and histamine potentiation is nearly absent in receptors with the double mutation. Based on our homology model, these two amino acid residues are not close enough to form a salt bridge directly (**Figure [7](#F7){ref-type="fig"}**). However, the crystal structure is derived from a homopentameric receptor in a ligand bound state with the artificial agonist benzamidine. Though this benzamidine binding site is found in the vicinity of Y157 ([@B23]), it might influence the overall structure of the extracellular domain, including the position of R120. However, an analysis with TRIDOCK ([@B38]) revealed that a putative small molecule ligand binding site exists between D163 and R120 (**Figure [7](#F7){ref-type="fig"}**). Furthermore, our docking analysis revealed that histamine can bind in various ways at this site (see **Figure [7](#F7){ref-type="fig"}** and Supplementary Figure [2](#SM1){ref-type="supplementary-material"}) with a comparably low predicted binding affinity \[ΔG(bind) = -3.9 to --3.7 kcal/mol\], which is in agreement with our comparably low histamine affinities measured experimentally. At the found docking positions, the histamine ammonium headgroup interacts majorly with D163(β), and thus probably weakens the R120/D163 interaction, which is in agreement with our experimental results. Furthermore, the docking positions found are in good agreement with the binding positions found by TRIDOCK. This position therefore could be a binding site for histamine, as well.

On the basis of our investigations, we suggest that histamine interacts with D163 on the β subunit and weakens the interaction of D163 with R120, which could lead to enhanced or prolonged GABA binding, a left shift of the GABA EC~50~ and thereby to potentiation. Consequently, we propose that the amino acid D163 is essential for the modulation of GABA~A~Rs by histamine and possibly a part of the histamine binding site. We demonstrate with our results a further function of the interaction of the α and β subunit mediated by D163 with R120, which is vital for both histamine potentiation and GABA affinity. The amino acid D163 is conserved in all β subunits of the GABA~A~Rs. In addition, amino acids homologous to D163 could be detected in the α1 subunit of the GlyR and α7 subunit of the nAChRs ([@B10]; [@B24]). The homologous amino acid in the nAChR is involved in the change of the affinity for calcium and acetylcholine ([@B10]).

Conclusion
==========

Our data show that histamine's potentiation depends on amino acid D163 of the β subunit and R120 of the α subunit. Interaction of these amino acids lowers the EC~50~ for GABA ([@B20]). We propose that histamine potentiates GABA~A~Rs by influencing this interaction and that these amino acids are part of a potential histamine binding site.
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